<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-08-04">August 4, 2016.</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Ferrata</forename><surname>Storti</surname></persName>
						</author>
						<author role="corresp">
							<persName><forename type="first">Christian</forename><surname>Straka</surname></persName>
							<email>cstraka@schoen-kliniken.de</email>
							<affiliation key="aff0">
								<orgName type="department">Schön Klinik Starnberger See</orgName>
								<address>
									<settlement>Berg</settlement>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Medizinische Klinik und Poliklinik IV</orgName>
								<orgName type="institution">Universität München (LMU)</orgName>
								<address>
									<settlement>Klinikum</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Liebisch</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">Universitätsklinikum Ulm</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hans</forename><surname>Salwender</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution">Asklepios Klinik Altona</orgName>
								<address>
									<settlement>Hamburg</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Burkhard</forename><surname>Hennemann</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution">Universitätsklinikum Regensburg</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bernd</forename><surname>Metzner</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Klinikum Oldenburg</orgName>
								<address>
									<settlement>Oldenburg</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><surname>Knop</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">Universitätsklinikum Tübingen</orgName>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="institution">Universitätsklinikum Würzburg</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sigrid</forename><surname>Adler-Reichel</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Medizinische Klinik und Poliklinik IV</orgName>
								<orgName type="institution">Universität München (LMU)</orgName>
								<address>
									<settlement>Klinikum</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Gerecke</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution">HELIOS Klinikum Berlin-Buch</orgName>
								<address>
									<settlement>Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hannes</forename><surname>Wandt</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution">Klinikum Nürnberg Nord</orgName>
								<address>
									<settlement>Nürnberg</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Bentz</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">Städtisches Klinikum Karlsruhe</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tim</forename><forename type="middle">Hendrik</forename><surname>Bruemmendorf</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">Universitätsklinikum Hamburg-Eppendorf</orgName>
								<address>
									<settlement>Hamburg</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marcus</forename><surname>Hentrich</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution">Städtisches Klinikum München-Harlaching</orgName>
								<address>
									<settlement>München</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Pfreundschuh</surname></persName>
							<affiliation key="aff13">
								<orgName type="institution">Universitätsklinikum des Saarlandes</orgName>
								<address>
									<settlement>Homburg</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hans-Heinrich</forename><surname>Wolf</surname></persName>
							<affiliation key="aff14">
								<orgName type="institution">Universitätsklinikum Halle</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Orhan</forename><surname>Sezer</surname></persName>
							<affiliation key="aff15">
								<orgName type="institution">Universitätsklinikum Charité</orgName>
								<address>
									<settlement>Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ralf</forename><surname>Bargou</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution">Universitätsklinikum Würzburg</orgName>
							</affiliation>
							<affiliation key="aff15">
								<orgName type="institution">Universitätsklinikum Charité</orgName>
								<address>
									<settlement>Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wolfram</forename><surname>Jung</surname></persName>
							<affiliation key="aff16">
								<orgName type="institution">Universitätsklinikum Göttingen</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lorenz</forename><surname>Trümper</surname></persName>
							<affiliation key="aff16">
								<orgName type="institution">Universitätsklinikum Göttingen</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bernd</forename><surname>Hertenstein</surname></persName>
							<affiliation key="aff17">
								<orgName type="institution">Klinikum Bremen-Mitte</orgName>
								<address>
									<settlement>Bremen</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Else</forename><surname>Heidemann</surname></persName>
							<affiliation key="aff18">
								<orgName type="institution">Diakonie Klinikum Stuttgart</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Helga</forename><surname>Bernhard</surname></persName>
							<affiliation key="aff19">
								<orgName type="laboratory">Klinikum rechts der Isar</orgName>
								<orgName type="institution">Technische Universität München</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nicola</forename><surname>Lang</surname></persName>
							<affiliation key="aff20">
								<orgName type="institution">Medizinische Klinik und Poliklinik III</orgName>
								<address>
									<settlement>Klinikum</settlement>
								</address>
							</affiliation>
							<affiliation key="aff21">
								<orgName type="institution">Universität München (LMU)</orgName>
								<address>
									<addrLine>22 HSK Dr. Horst Schmidt Klinik</addrLine>
									<settlement>Wiesbaden</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Norbert</forename><surname>Frickhofen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Holger</forename><surname>Hebart</surname></persName>
							<affiliation key="aff22">
								<orgName type="institution">Stauferklinikum Schwäbisch Gmünd</orgName>
								<address>
									<settlement>Mutlangen</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ralf</forename><surname>Schmidmaier</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Medizinische Klinik und Poliklinik IV</orgName>
								<orgName type="institution">Universität München (LMU)</orgName>
								<address>
									<settlement>Klinikum</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><surname>Sandermann</surname></persName>
							<affiliation key="aff23">
								<orgName type="institution">WISP Research Institute</orgName>
								<address>
									<settlement>Langenfeld</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tobias</forename><surname>Dechow</surname></persName>
							<affiliation key="aff19">
								<orgName type="laboratory">Klinikum rechts der Isar</orgName>
								<orgName type="institution">Technische Universität München</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Albrecht</forename><surname>Reichle</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution">Universitätsklinikum Regensburg</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Brigitte</forename><surname>Schnabel</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Schön Klinik Starnberger See</orgName>
								<address>
									<settlement>Berg</settlement>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Medizinische Klinik und Poliklinik IV</orgName>
								<orgName type="institution">Universität München (LMU)</orgName>
								<address>
									<settlement>Klinikum</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kerstin</forename><surname>Schäfer-Eckart</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution">Klinikum Nürnberg Nord</orgName>
								<address>
									<settlement>Nürnberg</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Langer</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">Universitätsklinikum Ulm</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Gramatzki</surname></persName>
							<affiliation key="aff24">
								<orgName type="institution">Universitätsklinikum Kiel</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Axel</forename><surname>Hinke</surname></persName>
							<affiliation key="aff23">
								<orgName type="institution">WISP Research Institute</orgName>
								<address>
									<settlement>Langenfeld</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bertold</forename><surname>Emmerich</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Medizinische Klinik und Poliklinik IV</orgName>
								<orgName type="institution">Universität München (LMU)</orgName>
								<address>
									<settlement>Klinikum</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hermann</forename><surname>Einsele</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">Universitätsklinikum Tübingen</orgName>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="institution">Universitätsklinikum Würzburg</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-08-04">August 4, 2016.</date>
						</imprint>
					</monogr>
					<idno type="MD5">1DF636328ECEC250E9F19E111227DC9B</idno>
					<idno type="DOI">10.3324/haematol.2016.151860</idno>
					<note type="submission">Received: July 1, 2016. Accepted: August 3, 2016.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:31+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>A utologous transplantation is controversial for older patients with multiple myeloma.</s><s>The role of age-adjusted high-dose melphalan and the impact of induction chemotherapy cycles is still unclear.</s><s>A total of 434 patients aged 60-70 years were randomly assigned to 4 cycles of standard anthracycline-based induction chemotherapy or no induction.</s><s>For all patients, double autologous transplantation after melphalan 140 mg/m 2 (MEL140) was planned.</s><s>The primary end point was progression-free survival.</s><s>Of 420 eligible patients, 85% received a first transplant and 69% completed double transplantation.</s><s>Treatment duration was short with a median of 7.7 months with induction chemotherapy cycles and 4.6 months without induction.</s><s>On an intention-to-treat basis, median progression-free survival with induction chemotherapy cycles (207 patients) was 21.4 months versus 20.0 months with no induction cycles (213 patients) (hazard ratio 1.04, 95% confidence interval 0.84-1.28;</s><s>P=0.</s><s>36).</s><s>Per protocol, progression-free survival was 23.7 months versus 23.0 months (P=0.28).</s><s>Patients aged 65 years or over (55%) did not have an inferior outcome.</s><s>Patients with low-risk cytogenetics [absence of del17p13, t(4;14) and 1q21 gains] showed a favorable overall survival and included the patients with sustained first remission.</s><s>MEL140 was associated with a low rate of severe mucositis (10%) and treatment-related deaths (1%).</s><s>Based on hazard ratio, the short treatment arm consisting of mobilization chemotherapy and tandem MEL140 achieved 96% of the progression-free survival, demonstrating its value as an independent component of therapy in older patients with multiple myeloma who are considered fit for autologous transplantation.</s><s>(clinicaltrials.gov</s><s>identifier: 02288741)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>5]<ref type="bibr" target="#b5">[6]</ref> As a consequence, many older but otherwise fit patients are excluded from the procedure.</s><s>This may have contributed to a survival disadvantage. <ref type="bibr" target="#b6">7</ref></s><s>oncerns about toxicity or an inferior outcome in comparison to younger patients continue to inhibit the application of high-dose therapy with ASCT in older patients, although its use has increased considerably in recent years. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b8">9</ref></s><s>1]<ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b17">[17]</ref> The little information there is concerning higher age groups is based on retrospective single center experience.</s><s>9]<ref type="bibr" target="#b20">[20]</ref><ref type="bibr" target="#b21">[21]</ref><ref type="bibr" target="#b22">[22]</ref><ref type="bibr" target="#b23">[23]</ref> Registry data are lacking details of toxicity and outcome but demonstrate improvements in overall survival (OS) over the years. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b8">9</ref></s><s>elphalan 200 mg/m 2 (MEL200) represents the standard high-dose regimen for the younger patient population. <ref type="bibr" target="#b24">24</ref></s><s>he frequent reluctance to apply MEL200 in patients over the age of 65 years is related to concerns about potential higher toxicity.</s><s>As an alternative to MEL200, an ageadjusted melphalan dose of 140 mg/m 2 (MEL140) <ref type="bibr" target="#b25">25</ref> can be given in patients over 60 years of age; the intention is to decrease severe mucositis and other toxicities and thereby to enable older patients who are not considered eligible for MEL200 to proceed to ASCT.</s><s>Reports show that this strategy has now become part of current clinical routine. <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b18">18,</ref><ref type="bibr" target="#b20">20,</ref><ref type="bibr" target="#b21">21,</ref><ref type="bibr" target="#b23">23</ref></s><s>The proportion of patients receiving an ageadjustment of the melphalan dose is steadily increasing within the higher age groups when considering patients over the age of 60, over 65 and over 70 years. <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b20">20,</ref><ref type="bibr" target="#b21">21,</ref><ref type="bibr" target="#b23">23</ref></s><s>If ageadjustment were to be applied consistently, many more older patients could be considered candidates for ASCT.</s></p><p><s>Two randomized clinical trials investigated intermediate-dose melphalan (MEL100) with ASCT in older patients. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b26">26</ref></s><s>Data from a prospective randomized trial specifically reporting the efficacy and toxicity of MEL140 in older patients has been lacking; this study aims to provide this missing information.</s></p><p><s>Historically, stem cell therapy is preceded by 3-6 cycles of induction chemotherapy.</s><s>This strategy is considered to be important but since the progression-free survival (PFS) achieved after ASCT is achieved from the complete treatment, the contribution of induction chemotherapy alone still has to be defined.</s><s>In the prospective phase III trial presented here, we addressed: 1) the role of conventional induction chemotherapy cycles prior to high-dose chemotherapy by randomization between anthracycline-based induction (the standard therapeutic approach when the trial started) and no induction cycles; and 2) the real toxicity and efficacy of tandem MEL140 with and without induction chemotherapy in a large older patient population.</s><s>Patients with no previous chemotherapy or a maximum of one cycle were randomly assigned between conventional induction chemotherapy cycles and a short course of dexamethasone only (Figure <ref type="figure" target="#fig_0">1A</ref>).</s><s>The study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, and was approved by the local ethics committees at each participating center.</s><s>Patients were required to provide written informed consent before enrollment.</s><s>The study was registered at clinicaltrials.gov</s><s>identifier: 02288741.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and study design</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment plan</head><p><s>In the induction arm, patients received 4 cycles of conventional anthracycline-dexamethasone-based regimens: vincristine-doxorubicin-dexamethasone (VAD), <ref type="bibr" target="#b27">27</ref> idarubicin-dexamethasone (ID), <ref type="bibr" target="#b28">28</ref> cyclophosphamide-doxorubicin-dexamethasone (CAD). <ref type="bibr" target="#b29">29</ref></s><s>n the no induction arm, patients received only 40 mg oral dexamethasone on days 1-4 and 8-11 for symptom control.</s><s>For the subsequent stem-cell mobilization, age-adjusted (75% dose) ifosfamide-epirubicin-etoposide (IEV) with granulocyte-colony stimulating factor (G-CSF) was recommended. <ref type="bibr" target="#b30">30</ref></s><s>The target dose for stem cell collection was 6x10 6 CD34-positive cells/kg (two transplants and one back-up).</s><s>The standard dose for each transplantation was 2x10 6 CD34-positive cells/kg.</s><s>High-dose melphalan at a total dose of 140 mg/m 2 (MEL140) was given in two doses of 70 mg/m 2 on days -3 and -2.</s><s>ASCT was performed on day 0. A second MEL140 course was planned two months after the first.</s><s>No maintenance treatment was given but regular bisphosphonate administration was recommended.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sample size and statistical aspects</head><p><s>The primary study end point was PFS calculated from the time point of randomization.</s><s>To detect a 10-month advantage in PFS for the induction arm [24-34 months, corresponding to a hazard ratio (HR) of 0.71] with a power of 80% and based on a one-sided type I error rate of 0.05, at least 132 patients were required per randomization arm.</s></p><p><s>Toxicity of treatment was evaluated using Common Toxicity Criteria (v.2.0, 1999), the definition of remission followed European Group for Blood and Marrow Transplantation (EBMT) criteria. <ref type="bibr" target="#b31">31</ref></s><s>Except for the primary end point, all analyses were descriptive or explorative in nature, providing two-sided P-values without referring to a specified error level.</s><s>No adjustments were made for multiple testing.</s><s>Proportions were eventually compared using Fisher's exact or χ² test.</s><s>All time-to-event end points were calculated by the Kaplan-Meier method.</s><s>Survival curves were compared using the log-rank test.</s><s>HR with confidence intervals were derived from Cox models.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients</head><p><s>Figure <ref type="figure" target="#fig_0">1</ref> shows the study design and the consort diagram.</s><s>A total of 434 patients were enrolled into the study protocol and were randomized.</s><s>Fourteen patients (3%) were excluded from analysis.</s><s>Accordingly, 420 patients could be analyzed with respect to the primary end point: PFS.</s><s>The median follow-up period was 5.2 years (range 0-10.1 years).</s><s>Details of consecutive treatment steps were documented in 416 patients.</s><s>Baseline characteristics of patients are shown in Table <ref type="table" target="#tab_1">1</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Induction chemotherapy</head><p><s>In the induction arm (n=207 patients), 98% received one of the recommended induction regimens (idarubicin-dexamethasone 67%, vincristine-doxorubicin-dexamethasone 25%, cyclophosphamide-doxorubicin-dexamethasone 6%), 2% received dexamethasone alone.</s><s>A median of 4 cycles (range 1-7 cycles) were given for a median of 3.9 months (range 0.3-12.3</s><s>months).</s><s>In the no induction arm, the 2 cycles of 4x40 mg dexamethasone were given for a median of 0.7 months (range 0-5.7 months) before stem cell mobilization was initiated.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Stem-cell mobilization and ASCT</head><p><s>A total of 385 patients (92%) were treated with stem cell mobilization chemotherapy: ifosfamide-epirubicinetoposide in 89%, cyclophosphamide-doxorubicin-dexamethasone in 5%, cyclophosphamide in 4%, cyclophoshaematologica | 2016; 101(11)  phamide-etoposide in 1%, ifosfamide in 1%.</s><s>Stem cells were collected in 376 patients.</s><s>The recommended target value (≥6x10 6 CD34 + cells/kg) and the required dose for a double transplantation (≥4x10 6 CD34 + cells/kg) were achieved in 80% and 90% of patients, respectively.</s><s>A total of 357 patients (85%) then went on to receive at least one transplant and 289 patients (69%) completed a double transplant.</s><s>The main reasons for drop-out in the 68 patients (16%) who did not receive the second transplant were: progression of disease (21%), toxicity (22%), death (7%), patient refusal (18%), insufficient stem cell collection (7%).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Toxicity, deaths and second primary malignancies</head><p><s>The major grade III/IV non-hematologic toxicities were infection and mucositis (Table <ref type="table">2</ref>).</s><s>Deaths up to 100 days from the last treatment occurred in 25 patients (6.0%) and death was due to: disease progression in 5 patients (1.2%), toxicity (infection, sepsis, renal failure, cardiac) in 20 patients (4.8%).</s><s>In 20 of 25 cases, death occurred before the first MEL140.</s><s>Transplant-related mortality (TRM) was very low: 1.4% after the first MEL140 and, notably, 0% following the second MEL140.</s><s>Some cases of grade III/IV mucositis were seen during induction chemotherapy cycles (4%), but none were observed during the short dexamethasone pre-phase.</s><s>Comparison of the induction and the no induction arms showed: 2% versus 6% grade III/IV mucositis after mobilization, 11% versus 16% after the first MEL140 course, 5% versus 7% for the second MEL140, respectively.</s><s>Moderate rates of grade III/IV infections occurred during induction chemotherapy cycles or the dexamethasone pre-phase (17% vs. 4%), after mobilization (17% vs. 30%), and at a higher frequency after the first MEL140 (35% vs. 44%) and second MEL140 (38% vs. 34%).</s><s>A second primary malignancy was reported (2 solid tumors, 2 acute myeloid leukemias) in 4 of 420 patients (1%).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Response rates</head><p><s>Response rates reflected differences in treatment and treatment progress between patients in the two arms (Table <ref type="table" target="#tab_3">3</ref>).</s><s>There was an initial lag in response rate in the no induction arm.</s><s>However, this recovered in the following treatment steps, and after the second MEL140 response rates were similar in the two arms.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Long-term outcomes after randomization</head><p><s>Median PFS for patients in the induction arm was 21.4 months compared to 20.0 months for patients in the no induction arm [hazard ratio (HR) for progression or death 1.04, 95% confidence interval (CI) 0.84-1.28;</s><s>P=0.36] (Figure <ref type="figure">2A</ref>).</s><s>Therefore, based on this HR, 96% of the duration of PFS was already achieved by ASCT alone; induction chemotherapy cycles contributed only 4%.</s><s>Treatment duration was short with a median of 7.7 months in patients in the induction arm and a median of 4.6 months in patients in the no induction arm.</s><s>For double transplant recipients (per protocol), median PFS was 23.7 months for patients in the induction arm compared to 23.0 months for patients in the no induction arm (P=0.28)</s><s>(Figure <ref type="figure">2B</ref>).</s><s>In the intention-to-treat analysis, median OS for patients in the induction arm was 53.4 months compared to 55.9 months for patients in the no induction arm (HR for death 1.01, 95%CI: 0.77-1.32;</s><s>P=0.95).</s><s>Per protocol (double transplants), the median OS for patients in the induction arm was 68.5 months compared to 64.4 for patients in the no induction arm (P=0.98).</s><s>A subgroup of 27 patients (6.4%) from both arms were survivors in first remission at five years.</s><s>Among these 27 patients, characterized by the presence of low-risk cytogenetics (100%), 96% received MEL140, 85% received a double transplant, and 70% were not in ISS stage III.</s><s>In 16 of these patients, no relapses were seen beyond five years.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment effects according to age subgroups</head><p><s>The discontinuation rate before the first high-dose melphalan course was higher for patients aged 65-70 years (18%) than for those aged 60-64 years (9%).</s><s>The drop-out rate after the first MEL140 was similar for the younger (18%) and the older (17%) patients.</s><s>More patients aged 60-64 years than aged 65-70 years completed tandem MEL140 (73% vs. 65%).</s><s>Deaths within 100 days from the last treatment were more frequent during the induction phase in patients aged 65-70 years (6.1% vs. 3.1%), but were similar in both age groups following the first transplant (1.6% vs. 1.1%) and did not occur in either age haematologica | 2016; 101(11)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Long-term outcomes after randomization between induction chemotherapy cycles and no induction cycles. The curves for progression-free survival with induction chemotherapy cycles versus no induction cycles are shown based on intention-to-treat (A) and per protocol (tandem transplants) (B).</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>A B</head><p><s>Progression-free survival rate Progression-free survival rate group after the second transplant.</s><s>On the intention-totreat basis, median PFS in younger versus older patients (19.5 and 22.1 months; P=0.23) and median OS (56.3 and 53.1 months; P=0.58) were similar (Figure <ref type="figure" target="#fig_1">3A</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cytogenetic risk and outcome</head><p><s>Of the 210 evaluated patients, 108 patients (51%) fulfilled the IMWG <ref type="bibr" target="#b32">32,</ref><ref type="bibr" target="#b33">33</ref> low-risk cytogenetics criteria: absence of translocation (4;14), deletion 17p13, amplification of 1q21.2) (Table <ref type="table" target="#tab_1">1</ref>).</s><s>High-risk cytogenetics [presence of translocation (4;14) and/or deletion 17p13] were found in 21%, intermediate-risk cytogenetics [presence of amplification of 1q21.2, absence of translocation (4;14) and deletion (17p13)] were present in 28% of cases.</s><s>A highly significant difference between low-risk and high-risk cytogenetics was seen for PFS (median 23.5 vs. 14.9 months; P&lt;0.0001) and OS (median 74.7 vs. 32.9</s><s>months; P&lt;0.0001) (Figure <ref type="figure" target="#fig_1">3B</ref>).</s><s>The patients with low-risk cytogenetics who completed double transplantation (78%) had an excellent outcome (median PFS 26.7 months and median OS 87.4 months).</s><s>Patients still alive in sustained first remission beyond five years were considered to be in the low-risk cytogenetics group.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>Our trial abandoned induction chemotherapy cycles before ASCT in one arm of the study in order to test the relationship between induction chemotherapy and ASCT, and did not use consolidation or maintenance therapy.</s><s>This must be considered when comparing the outcome of our trial to others which applied the common strategy of incorporating all available drugs into treatment phases before and after ASCT with the aim of achieving a maximum duration of PFS after first-line treatment in MM patients.</s><s>Unexpectedly, we found that a large part of the anti-tumor effect (96%) was achieved with high-dose chemotherapy and ASCT alone, and that the 4 cycles of anthracycline-based induction chemotherapy only made a small contribution.</s><s>By 3-4 months of anthracycline-based induction therapy, the PFS was improved by only two months.</s><s>Based on the HR of the comparison between the two arms, such induction chemotherapy cycles achieved only 4% of the PFS.</s><s>Anthracycline-based induction chemotherapy was the standard approach when our trial started but has since been replaced by induction regimens incorporating novel agents.</s><s>In this respect, both arms of Autotransplant in older multiple myeloma patients haematologica | 2016; 101 (11)  1403</s></p><p><s>Table <ref type="table">2</ref>. Hematologic and non-hematologic toxicity during treatment steps.</s><s>our trial may be regarded as a 'baseline' from which the achievements of novel agent-based induction therapy can be evaluated.</s><s>The current use of bortezomib-based induction regimens, <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b34">[34]</ref><ref type="bibr" target="#b35">[35]</ref><ref type="bibr" target="#b36">[36]</ref> were found to increase the PFS over the typical anthracycline-based regimen VAD <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b14">15</ref> by approximately six months.</s><s>Despite this improvement, the estimated impact of such induction therapy on the overall PFS appears to be limited when we consider our 'baseline' results and those from other trials demonstrating a high efficacy of post-transplant treatments with novel agents. <ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b13">14</ref></s><s>Our study is the first prospective randomized trial to characterize the 'real' toxicity and efficacy of MEL140 with ASCT in older MM patients.</s><s>The results highlight an independent role for ASCT in older patients.</s><s>MEL140 was well-tolerated.</s><s>The rate of severe mucositis was approximately 10%, TRM approximately 1%.</s><s>It should be emphasized that following the treatment pause after the first MEL140, the non-hematologic toxicity of the second MEL140 appeared to be a little lower to the first MEL140 and the TRM was 0%.</s><s>Importantly, the long-term outcome identified a subgroup of patients who did not relapse after MEL140 even over a number of years.</s><s>This may indicate some curative potential with ageadjusted high-dose melphalan.</s><s>For more than 200 patients aged 65-70 years, the outcome was at least as good compared to the younger patients in this study, demonstrating that an age cut off at 65 years for MEL140 was not relevant.</s><s>The long-term outcome for the tandem MEL140 component in conjunction with the large number of patients treated may serve as a point of reference for future trials.</s><s>Geriatric assessment and comorbidity scores will be helpful to encourage autologous transplantation in many MM older patients. <ref type="bibr" target="#b37">37,</ref><ref type="bibr" target="#b38">38</ref></s><s>The low rate of second primary malignancies following tandem MEL140 in comparison to that in the published literature <ref type="bibr" target="#b39">39</ref> is noteworthy and could be related to the limited first-line treatment in the study population.</s></p><p><s>Due to the significant efforts of a central laboratory, we can present up-to-date cytogenetic data for around 200 patients.</s><s>Many publications define high-risk versus stan-</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>A B</head><p><s>dard-risk groups but very few reports indicate a low-risk group as defined by the IMWG. <ref type="bibr" target="#b33">33,</ref><ref type="bibr" target="#b34">34</ref></s><s>This requires investigation of 1q21 gains together with analysis of translocation (4;14) and deletion 17p.</s><s>We found that 50% of the MM patients of this age group who had a low-risk cytogenetic profile showed excellent survival rates with front-line ageadjusted high-dose melphalan.</s><s>Importantly, the patients with low-risk cytogenetics included those with sustained unmaintained first remission, and some of these could be considered 'cured'.</s><s>Recently, treatment with novel agents plus ASCT has been found to be more effective than novel agents plus conventional chemotherapy in patients up to 65 years of age. <ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b17">17</ref></s><s>Similar randomized clinical trials are also needed in the older patient population and treatment should be based on tandem MEL140.</s></p><p><s>Another important aspect to consider is that the concept of age-adjusted high-dose melphalan includes double transplantation, which compensates the dose reduction of single melphalan.</s><s>The tandem MEL100 regimen divided the standard MEL200 dose in two parts and enabled older patients to proceed to ASCT with reduced toxicity. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b26">26,</ref><ref type="bibr" target="#b40">40</ref></s><s>A tandem application of MEL200 in older patients, however, was found to decrease steeply with higher age due to the well-known risks associated with these patients. <ref type="bibr" target="#b22">22</ref></s><s>In contrast, in our trial, a rapid improvement in performance status post transplant allowed the second MEL140 course to be given after two months in approximately 80% of patients.</s><s>Therefore, as far as feasibility is concerned, tandem MEL140 (cumulative melphalan dose 280 mg/m 2 ) represents an alternative to single MEL200 (200 mg/m 2 ) in the older patient population.</s><s>Such a comparison should be investigated in a prospective randomized trial for patients aged 60-70 years.</s></p><p><s>In fact, our trial shows that the treatment arm consisting of stem-cell mobilization chemotherapy followed by tandem MEL140 with ASCT, despite its short treatment time of 4-5 months, is extremely effective, with a PFS of 20-23 months.</s><s>Current non-transplant regimens used in this age group, such as VMP <ref type="bibr" target="#b41">41</ref> or MPT <ref type="bibr" target="#b42">42</ref> or MPR <ref type="bibr" target="#b43">43</ref> or Rd, <ref type="bibr" target="#b44">44</ref> provide similar PFS rates (median 22, 20, 14 and 21 months, respectively) but are associated with the development of neuropathy or thrombosis and thromboembolism and require a prolonged treatment time that often does exceed one year.</s><s>On the other hand, our trial demonstrates that age-adjusted high-dose therapy is not necessarily 'aggressive', nor is this 'aggressiveness' observed in all patients.</s><s>Older fit patients may, therefore, benefit from an ageadjusted transplant program that would allow longer unmaintained remissions following transplantation during which patients can enjoy freedom-from-therapy.</s><s>When lenalidomide is continued as maintenance therapy in the MPRR <ref type="bibr" target="#b43">43</ref> or continues Rd <ref type="bibr" target="#b44">44</ref> regimens, the PFS can be extended.</s><s>Similarly, lenalidomide maintenance can also be used after MEL140. <ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b40">40</ref></s><s>The preference for MEL140 or MEL200 in subgroups of older patients is beyond the scope of the present paper as this has been discussed extensively in previous publications.</s><s>The known arguments center around the specific features of MEL200 (higher toxicity, potentially higher efficacy, single transplantation, upper age limit around 70 years) versus MEL140 (lower toxicity, potentially lower efficacy, tandem transplantation possible, upper age limit around 75 years).</s><s>Obviously, any valid recommendation can only be made on the basis of the availability of results from prospective randomized trials in specific age groups which, however, are completely lacking.</s><s>Therefore, for the moment, MEL140 and MEL200 represent complementary rather than competing options for older patients.</s><s>In conclusion, short-term tandem MEL140 with ASCT can lead to long-lasting unmaintained remission, and should be considered an independent component of myeloma therapy.</s><s>A sustained first remission is associated with low-risk cytogenetics present in approximately 50% of patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p><s>Novartis provided financial support for conducting the study, but was not involved in data collection, data analysis or writing the manuscript.</s><s>Molecular cytogenetic analysis was supported by the Deutsche José Carreras Leukämie-Stiftung.</s></p><p><s>Autotransplant in older multiple myeloma patients haematologica | 2016; 101 (11)</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .B</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Study design and consort diagram.</s><s>(A) Study design.</s><s>Patients were randomized (R) to the two study arms: 1) induction chemotherapy cycles; and 2) no induction cycles.</s><s>(B) Consort diagram.</s><s>Inclusion, randomization, treatment and follow up of enrolled patients.</s><s>PBSCs: peripheral blood stem cells; ICC: induction chemotherapy cycles; Dex: dexamethasone; Mob: mobilization chemotherapy; MEL140: high-dose melphalan.</s></p></div></figDesc><graphic coords="3,106.92,213.02,403.90,513.84" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 3 .</head><label>3</label><figDesc><div><p><s>Figure 3. Outcome for age and cytogenetic risk groups.</s><s>The curves for progression-free survival and overall survival are shown for (A) the age groups 60-64 years and 65-70 years, and (B) for high-risk, intermediate-risk and low-risk cytogenetics.</s></p></div></figDesc><graphic coords="7,97.85,329.87,425.14,417.22" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="5,318.16,57.93,229.55,379.99" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc><div><p><s>This randomized multicenter trial was planned by the German Multiple Myeloma Study Group (DSMM) and was conducted at40 sites.</s><s>Eligible patients had newly diagnosed stage II or III MM according to Durie and Salmon and were 60-70 years of age.</s><s>Additional criteria for inclusion were an Eastern Cooperative Oncology Group performance status of 0-2, adequate organ function, and absence of uncontrolled infection.</s><s>Enrollment began in August 2001 and ended in August 2006.</s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Patients' characteristics.</s></p></div></figDesc><table><row><cell>Randomization</cell></row></table><note><p><s>*ISS: International Staging System.</s><s>† Hyperdiploid myeloma was assessed by the presence of gains of 9q34.2 ǂ Data from either central or local cytogenetic laboratory.</s><s>ll High: presence of t (4;14) and/or del 17p13.</s><s>§ Intermediate: presence of +1q21.2 and absence of t(4;14) and del 17p13.</s><s>¶ Low: absence of t (4;14), del 17p13 and +1q21.2 in patients with analysis of all these three characteristics.</s><s>°Cut-off of aberrant cells: 20%; SD: standard deviation.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>140 Induction No induction Induction No induction Induction No induction Induction No induction</head><label></label><figDesc></figDesc><table><row><cell cols="8">Induction phase 2. MEL Hematologic (%) Mobilization 1. MEL 140</cell><cell></cell></row><row><cell>Anemia</cell><cell>84</cell><cell>64</cell><cell>89</cell><cell>95</cell><cell>100</cell><cell>100</cell><cell>100</cell><cell>100</cell></row><row><cell>Leukopenia</cell><cell>59</cell><cell>26</cell><cell>86</cell><cell>88</cell><cell>100</cell><cell>100</cell><cell>100</cell><cell>100</cell></row><row><cell>Neutropenia</cell><cell>47</cell><cell>15</cell><cell>77</cell><cell>82</cell><cell>100</cell><cell>100</cell><cell>100</cell><cell>100</cell></row><row><cell>Grade III/IV</cell><cell>22</cell><cell>5</cell><cell>63</cell><cell>75</cell><cell>100</cell><cell>100</cell><cell>100</cell><cell>100</cell></row><row><cell>Thrombocytopenia</cell><cell>27</cell><cell>16</cell><cell>77</cell><cell>84</cell><cell>100</cell><cell>100</cell><cell>100</cell><cell>100</cell></row><row><cell>Grade III/IV</cell><cell>5</cell><cell>2</cell><cell>40</cell><cell>44</cell><cell>100</cell><cell>100</cell><cell>100</cell><cell>100</cell></row><row><cell>Non-hematologic (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Nausea</cell><cell>32</cell><cell>10</cell><cell>45</cell><cell>45</cell><cell>70</cell><cell>72</cell><cell>71</cell><cell>72</cell></row><row><cell>Grade III/IV</cell><cell>2</cell><cell>0</cell><cell>1</cell><cell>4</cell><cell>7</cell><cell>14</cell><cell>5</cell><cell>9</cell></row><row><cell>Vomiting</cell><cell>15</cell><cell>1</cell><cell>18</cell><cell>23</cell><cell>36</cell><cell>46</cell><cell>39</cell><cell>43</cell></row><row><cell>Diarrhea</cell><cell>11</cell><cell>2</cell><cell>13</cell><cell>18</cell><cell>41</cell><cell>42</cell><cell>31</cell><cell>34</cell></row><row><cell>Constipation</cell><cell>15</cell><cell>5</cell><cell>7</cell><cell>9</cell><cell>10</cell><cell>9</cell><cell>12</cell><cell>8</cell></row><row><cell>Mucositis</cell><cell>17</cell><cell>3</cell><cell>23</cell><cell>28</cell><cell>51</cell><cell>51</cell><cell>46</cell><cell>49</cell></row><row><cell>Grade III/IV</cell><cell>4</cell><cell>0</cell><cell>2</cell><cell>6</cell><cell>11</cell><cell>16</cell><cell>5</cell><cell>7</cell></row><row><cell>Infection</cell><cell>33</cell><cell>14</cell><cell>31</cell><cell>40</cell><cell>49</cell><cell>58</cell><cell>56</cell><cell>49</cell></row><row><cell>Grade III/IV</cell><cell>17</cell><cell>4</cell><cell>17</cell><cell>30</cell><cell>35</cell><cell>44</cell><cell>38</cell><cell>34</cell></row><row><cell>Dyspnea</cell><cell>11</cell><cell>6</cell><cell>5</cell><cell>11</cell><cell>13</cell><cell>10</cell><cell>10</cell><cell>6</cell></row><row><cell>Creatinine</cell><cell>18</cell><cell>22</cell><cell>17</cell><cell>23</cell><cell>25</cell><cell>19</cell><cell>16</cell><cell>16</cell></row><row><cell>MEL140: melphalan 140 mg/m 2 .</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Responses with consecutive treatment steps according to EBMT criteria.</s></p></div></figDesc><table><row><cell></cell><cell cols="2">Induction phase</cell><cell></cell><cell>Mobilization</cell><cell>1. MEl140</cell><cell></cell><cell cols="2">2. MEL140</cell></row><row><cell></cell><cell cols="2">Induction No induction</cell><cell cols="5">Induction No induction Induction No induction Induction</cell><cell>No induction</cell></row><row><cell>* ORR (%)</cell><cell>48</cell><cell>30</cell><cell>58</cell><cell>46</cell><cell>78</cell><cell>79</cell><cell>87</cell><cell>87</cell></row><row><cell>† CR (%)</cell><cell>0</cell><cell>1</cell><cell>2</cell><cell>2</cell><cell>6</cell><cell>9</cell><cell>17</cell><cell>12</cell></row><row><cell>‡ PR (%)</cell><cell>48</cell><cell>29</cell><cell>56</cell><cell>44</cell><cell>72</cell><cell>70</cell><cell>70</cell><cell>75</cell></row><row><cell>§ MR (%)</cell><cell>19</cell><cell>14</cell><cell>20</cell><cell>19</cell><cell>13</cell><cell>12</cell><cell>7</cell><cell>8</cell></row><row><cell>ǁ NC (%)</cell><cell>25</cell><cell>52</cell><cell>20</cell><cell>32</cell><cell>6</cell><cell>8</cell><cell>5</cell><cell>5</cell></row><row><cell>¶ PD (%)</cell><cell>7</cell><cell>4</cell><cell>2</cell><cell>3</cell><cell>3</cell><cell>2</cell><cell>2</cell><cell>0</cell></row><row><cell cols="9">EBMT: European Society for Blood and Marrow Transplantation; MEL140: melphalan 140 mg/m 2 .*ORR: overall response rate (CR+PR);  † CR: complete response;  ‡ PR: partial</cell></row><row><cell>response;  § MR: minimal response;</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>ǁ NC: no change; ¶ PD: progressive disease.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">haematologica | 2016; 101<ref type="bibr" target="#b10">(11)</ref> </note>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome</title>
		<author>
			<persName><forename type="first">M</forename><surname>Attal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Harousseau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Stoppa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">335</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="91" to="97" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Total therapy with tandem transplants for newly diagnosed multiple myeloma</title>
		<author>
			<persName><forename type="first">B</forename><surname>Barlogie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jagannath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Desikan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="55" to="65" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Child</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Davies</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">348</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="1875" to="1883" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma</title>
		<author>
			<persName><forename type="first">C</forename><surname>Dumontet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ketterer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Espinouse</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1037" to="1041" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial</title>
		<author>
			<persName><forename type="first">T</forename><surname>Facon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Mary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hulin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="issue">9594</biblScope>
			<biblScope unit="page" from="1209" to="1218" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Age is not a prognostic variable with autotransplants for multiple myeloma</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Siegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Desikan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mehta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="51" to="54" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dispenzieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Q</forename><surname>Lacy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1122" to="1128" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Auner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Szydlo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hoek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="209" to="215" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Older patients with myeloma derive similar benefit from autologous transplantation</title>
		<author>
			<persName><forename type="first">M</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Blood Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1796" to="1803" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Lenalidomide maintenance after stem-cell transplantation for multiple myeloma</title>
		<author>
			<persName><forename type="first">M</forename><surname>Attal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Lauwers-Cances</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Marit</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">366</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="1782" to="1791" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Cavo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tacchetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Patriarca</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">376</biblScope>
			<biblScope unit="issue">9758</biblScope>
			<biblScope unit="page" from="2075" to="2085" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Lenalidomide after stem-cell transplantation for multiple myeloma</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Mccarthy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Owzar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Hofmeister</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">366</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="1770" to="1781" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Harousseau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Attal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Avet-Loiseau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">30</biblScope>
			<biblScope unit="page" from="4621" to="4629" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Autologous transplantation and maintenance therapy in multiple myeloma</title>
		<author>
			<persName><forename type="first">A</forename><surname>Palumbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cavallo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="895" to="905" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial</title>
		<author>
			<persName><forename type="first">P</forename><surname>Sonneveld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">G</forename><surname>Schmidt-Wolf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Van Der Holt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="2946" to="2955" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title level="m" type="main">Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome</title>
		<author>
			<persName><forename type="first">M</forename><surname>Attal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Lauwers-Cances</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hulin</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>IFM/DFCI 2009 Trial</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page">391</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">d e -Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial</title>
		<author>
			<persName><forename type="first">F</forename><surname>Gay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Magarotto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Petrucci</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page">392</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years</title>
		<author>
			<persName><forename type="first">A</forename><surname>Badros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Barlogie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Siegel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="600" to="607" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Bashir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Parmar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Lymphoma</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="118" to="122" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma</title>
		<author>
			<persName><forename type="first">J</forename><surname>El Cheikh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kfoury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Calmels</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hematol Oncol Stem Cell Ther</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="30" to="36" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Gertz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Q</forename><surname>Lacy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dispenzieri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="605" to="611" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents</title>
		<author>
			<persName><forename type="first">M</forename><surname>Merz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Neben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Raab</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="189" to="195" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dingli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Q</forename><surname>Lacy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Hematol</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="614" to="617" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial</title>
		<author>
			<persName><forename type="first">P</forename><surname>Moreau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Facon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Attal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="731" to="735" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Multiple myeloma treated with high dose intravenous melphalan</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Selby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Mcelwain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Nandi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="55" to="62" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Palumbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bringhen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Petrucci</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="3052" to="3057" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Effective treatment of advanced multiple myeloma refractory to alkylating agents</title>
		<author>
			<persName><forename type="first">B</forename><surname>Barlogie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Alexanian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">310</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="1353" to="1356" />
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Douglas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename><surname>Mitchell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="605" to="612" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">adriamycin and dexamethasone (CAD) is a highly effective therapy for patients with advanced multiple myeloma</title>
		<author>
			<persName><forename type="first">H</forename><surname>Szelényi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Kreuser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Keilholz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="105" to="108" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Blood stem cell collections after mobilization with combination chemotherapy containing ifosfamide followed by G-CSF in multiple myeloma</title>
		<author>
			<persName><forename type="first">C</forename><surname>Straka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hebart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Adler-Reichel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Werding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Emmerich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Einsele</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncology</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="94" to="98" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bladé</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Samson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Reece</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1115" to="1123" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">IMWG consensus on risk stratification in multiple myeloma</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Chng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dispenzieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Chim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="269" to="277" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival</title>
		<author>
			<persName><forename type="first">H</forename><surname>Avet-Loiseau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Attal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Campion</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="1949" to="1952" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma</title>
		<author>
			<persName><forename type="first">P</forename><surname>Moreau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Avet-Loiseau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Facon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="5752" to="5758" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHE-MA/GEM study</title>
		<author>
			<persName><forename type="first">L</forename><surname>Rosiñol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oriol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">I</forename><surname>Teruel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1589" to="1596" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Richardson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lonial</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="679" to="686" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores</title>
		<author>
			<persName><forename type="first">M</forename><surname>Engelhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Dold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ihorst</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>In press</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the International Staging System are highly predictive for outcome</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kleber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ihorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gross</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Lymphoma Myeloma Leuk</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="541" to="551" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Large registry analysis to accurately define second malignancy rates and risks in a wellcharacterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years</title>
		<author>
			<persName><forename type="first">M</forename><surname>Engelhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ihorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Landgren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1340" to="1349" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results</title>
		<author>
			<persName><forename type="first">F</forename><surname>Gay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Magarotto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Crippa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1376" to="1383" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>San Miguel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schlag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Khuageva</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">359</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="906" to="917" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Thalidomide for previously untreated elderly patients with multiple myeloma: metaanalysis of 1685 individual patient data from 6 randomized clinical trials</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Fayers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Palumbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hulin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1239" to="1247" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Continuous lenalidomide treatment for newly diagnosed multiple myeloma</title>
		<author>
			<persName><forename type="first">A</forename><surname>Palumbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hajek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Delforge</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">366</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="1759" to="1769" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma</title>
		<author>
			<persName><forename type="first">L</forename><surname>Benboubker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Dimopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dispenzieri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="906" to="917" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
